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Atpresent we are witnessing an ongoing discussion about 
the requirement for specialization in internal medicine by phy-
sicians who want to pursue a professional carrier in narrow 
specialties originating from internal medicine. The discussion 
is fueled, in a sense, by the administrative decision to elimi-
nate medical outpatient clinics, which limits internal medicine 
to a hospital specialty. Nevertheless progress in medicine con-
tinuously confirms the priceless value of physician’s ability to 
form a broader picture based on patient complains, symptoms 
and results. Antiphospholipid syndrome is an example (one out 
of many) confirming this opinion.
 We can look at the history of antiphospholipid syndrome 
in two ways. Its laboratory features are tightly bound to the 
simple, nonspecific VDRL test, described in the forties which 
detects syphilis reagin. Cardiolipin, a negatively charged phos-
pholipid from the bovine heart served as an antigen in this test. 
It rapidly turned out that many subjects tested falsely positive 
and some of them suffered from systemic lupus erythematosus 
(SLE). In the fifties an anticoagulant had been described in the 
blood of SLE patients [1]; hence it has later coined name – lupus 
anticoagulant. 
Different observartions determine the clinicia’s view. By 
1954 an anticoagulant was reported in a women with a his-
tory of seven spontaneous abortions [2]. In 1963 Bowie et al. 
pointed out to the paradoxical coexistence of such an antico-
agulant with thrombotic complications [3].
In the beginning of the eighties a test was introduced with 
the use of cardiolipin (first radioimmunoassay, then enzyme-
linked immunoassay) to detect anticardiolipin antibodies. 
Many patients with SLE and these antibodies suffered from 
thrombotic complications [4]. At this point research groups 
from Great Britain, USA and France were coining a term: 
antiphospholipid syndrome, secondary to SLE. As early as in 
1980 professor Boffa described an association of lupus antico-
agulant with recurrent spontaneous abortions and thrombosis 
in a women with no symptoms of SLE; here a term of primary 
antiphospholipid syndrome appears. The first diagnostic crite-
ria, characteristic for antiphospholipid syndrome, are proposed 
which include the coexistence of clinical symptoms (recurrent 
abortions, venous and arterial thrombosis, thrombocytopenia) 
and laboratory features (the presence of lupus anticoagulant 
and/or anticardiolipin antibodies) [5]. Finally, in 1990 three 
research groups (from Europe, Japan and Australia) simulta-
neously reported that a protein – β2-glycoprotein I (β2-GPI) 
– is required for binding of antiphospholipid antibodies to 
negatively charged phospholipids [6].
Now lets take a 15-year long jump in time, to the year 
2005, or even to the beginning of 2006, and present a con-
temporary opinion on this fascinating syndrome. The princi-
pal symptom – vascular thrombosis – is an immune-media-
ted phenomenon. Antiphospholipid syndrome is probably the 
most frequently occurring autoimmune disease. Antiphos-
pholipid antibodies (aPL) are do not only interfere with the 
hemostatic system reactions mediated by negatively charged 
phospholipids but they also activate the endothelium [7]. In 
fact these antibodies are not directed against phospholipids 
but against domain I of β2-GPI. For this reason thrombotic 
complications are most closely associated with the presence of 
β2-GPI-dependent lupus anticoagulant and anti-β2-GPI an-
tibodies [8]. Thrombosis: arterial, most often manifested as 
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ischemic stroke; venous. mainly deep venous thrombosis of the 
lower extremities and affecting small vessels of many organs 
and tissues are most strongly associated and characteristic for 
this syndrome. Together with obstetric complications (mainly 
recurrent spontaneous abortions) those symptoms were in-
cluded among clinical classification criteria proposed in Sap-
poro in 1998 and published a year later [9]. The presence of 
lupus anticoagulant and anticardiolipin antibodies in medium 
or high titer were included among the laboratory criteria. But 
many other symptoms were passed over in silence. For this rea-
son these criteria has been updated recently during an experts’ 
meeting in Sydney (2004) and published at the beginning of 
2006 [10]. Leaving out many details important only for re-
search purposes, let’s concentrate on the changes important 
for the clinician (table). 
Among serological criteria antibodies against β2-GPI were 
added, at levels exceeding the 99 percentile of the healthy 
population. Two positive results are still mandatory, but now 
at least 12 weeks apart instead of six.
The most crucial changes affected clinical criteria and 
symptoms. The symptoms mentioned earlier remained, be-
cause of their sensitivity and specificity for the syndrome. 
However, a close attention is paid to their conformity with 
generally accepted definitions (e.g., pre-eclampsia, eclampsia, 
placental insufficiency, objective conformation of thrombosis). 
When the presence of aPL is confirmed, coronary artery dis-
ease, intracardiac thrombi, transient ischemic attacks (TIA) 
and histologically proven aPL-associated nephropathy, are all 
considered thrombosis related to antiphospholipid syndrome 
or its equivalent. 
An emphasis was placed on some clinical features quite fre-
quent in APS but not specific for the syndrome. These include: 
a/ cardiac valve disease, b/ livedo reticularis, and c/ throm-
bocytopenia. New terms were coined: aPL-associated cardiac 
valve disease, aPL-associated livedo reticularis, aPL-associated 
thrombocytopenia (see also aPL-associated nephropathy, men-
tioned above), and specific requirements for their diagnosis 
were given. The exact clinical significance of such symptoms 
associated with APL but not fulfilling definite criteria for APS 
deserves further study. 
Also the role of some other antiphospholipid antibodies 
(e.g., antiphosphatidylserine, antiphosphatidylethanolamine, 
antiprothrombin) awaits further clarification; providing they 
are not associated with classic APL antibodies.
Finally, it was advised against using the terms “primary” 
or “secondary” APS. Firstly because laboratory and clinical 
features are the same and secondly because in many patients 
with an initially primary form of disease a fully blown sys-
temic lupus erythrematosus eventually develops. 
Antiphospholipid syndrome is not a trivial problem. Isch-
emic stroke at a young age, recurrent obstetrical complications, 
and last but not least, the authentic risk of pulmonary embo-
lism and the development postthrombotic syndrome deserve 
decisive action. This is based mainly on effective antithrom-
botic treatment. Today it includes oral anticoagulants (INR 
2,0–3,0; in special situations – 3,5) and in pregnant women 
– heparins, mainly low molecular weight products.
Patients with APS may seek help from various physicians 
representing the internal medicine sub-specialties: rheumato-
Table. Updated classification criteria for the antiphospholipid syndrome 
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logists, hematologists, cardiologists, angiologists, clinical im-
munologists, but also: neurologists, obstetricians, dermatolo-
gists or vascular surgeons. The syndrome is just one of many 
examples, a pretext if one prefers, to emphasize how impor-
tant is a thorough training in internal medicine to properly 
diagnose and effectively treat these and similar patients. For 
a good internist fragmentary pieces of information converge 
like in a magnifying glass. It is him who picks these pieces 
together to offer the patient the best possible care. In this way 
the physician becomes an example of such a right and desir-
able relation in medicine: one patient – one doctor. It should 
be our ambition to provide such training to our fellow-physi-
cians, regardless of the motivation and necessity in achieving 
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